|
gptkbp:instanceOf
|
gptkb:drug
SGLT2 inhibitor
|
|
gptkbp:approvedBy
|
gptkb:FDA
2013
|
|
gptkbp:ATCCode
|
A10BK02
|
|
gptkbp:brand
|
Invokana
|
|
gptkbp:CASNumber
|
842133-18-0
|
|
gptkbp:chemicalFormula
|
C24H25FO5
|
|
gptkbp:contraindication
|
severe renal impairment
|
|
gptkbp:developedBy
|
gptkb:Mitsubishi_Tanabe_Pharma
gptkb:Janssen_Pharmaceuticals
|
|
gptkbp:drugClass
|
antidiabetic agent
|
|
gptkbp:eliminationHalfLife
|
10-13 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
canagliflozin
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits sodium-glucose co-transporter 2
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:reduces
|
blood glucose levels
|
|
gptkbp:riskFactor
|
lower limb amputation
bone fracture
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
urinary tract infection
hypotension
hyperkalemia
genital mycotic infection
increased urination
ketoacidosis
|
|
gptkbp:usedFor
|
gptkb:type_2_diabetes_mellitus
|
|
gptkbp:bfsParent
|
gptkb:SGLT2_inhibitors
|
|
gptkbp:bfsLayer
|
6
|